Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

Number 5: The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, ...

Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...